Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 19/20 | 0.71 |
| ▸ | TLR8 | Q9NR97 | 13/20 | 0.71 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15436858 | 0.89 | TLR7 (0.55) | TLR7TLR8NUDT1 | |
| SCHEMBL10090895 | 0.88 | TLR7 (0.67) | TLR7TLR8NUDT1 | |
| Resiquimod SCHEMBL34159 | 0.83 | TLR7 (1.00) | TLR7TLR8NUDT1 | |
| Resiquimod SCHEMBL21352711 | 0.83 | TLR7 (1.00) | TLR7TLR8NUDT1 | |
| Resiquimod SCHEMBL29358122 | 0.83 | TLR7 (1.00) | TLR7TLR8NUDT1 | |
| SCHEMBL24807103 | 0.83 | TLR7 (0.76) | TLR7TLR8NUDT1 | |
| SCHEMBL29639786 | 0.83 | TLR7 (0.76) | TLR7TLR8NUDT1 | |
| Resiquimod SCHEMBL2262583 | 0.83 | TLR7 (0.98) | TLR7TLR8NUDT1 | |
| Resiquimod SCHEMBL2266073 | 0.83 | TLR7 (0.98) | TLR7TLR8NUDT1 | |
| SCHEMBL5454764 | 0.83 | TLR7 (0.82) | TLR7TLR8NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160213776-A1 | ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2016-07-28 | — | — | US | disclosed |
| US-20160213776-A1 | ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2016-07-28 | — | — | US | disclosed |
| US-9375471-B2 | Adjuvanted formulations of booster vaccines | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2016-06-28 | — | — | US | disclosed |
| US-9375471-B2 | Adjuvanted formulations of booster vaccines | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2016-06-28 | — | — | US | disclosed |
| US-9315530-B2 | Adsorption of immunopotentiators to insoluble metal salts | NOVARTIS AG (CH) | 2016-04-19 | — | — | US | disclosed |
| US-9315530-B2 | Adsorption of immunopotentiators to insoluble metal salts | NOVARTIS AG (CH) | 2016-04-19 | — | — | US | disclosed |
| EP-2719395-A1 | Adsorption of immunopotentiators to insoluble metal salts | Novartis AG (CH) | 2014-04-16 | — | — | EP | disclosed |
| EP-2480253-B1 | ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS | NOVARTIS AG (CH) | 2014-01-22 | — | — | EP | disclosed |
| US-20130274465-A1 | ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS | IRM LLC (BM) | 2013-10-17 | — | — | US | disclosed |
| US-20130274465-A1 | ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS | IRM LLC (BM) | 2013-10-17 | — | — | US | disclosed |
| EP-2480253-A1 | ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS | Novartis AG (CH) | 2012-08-01 | — | — | EP | disclosed |
| US-20120177681-A1 | Formulation of immunopotentiators | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2012-07-12 | — | — | US | disclosed |
| US-20120177681-A1 | Formulation of immunopotentiators | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2012-07-12 | — | — | US | disclosed |
| WO-2012031140-A1 | ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS | NOVARTIS AG (CH) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012031140-A1 | ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS | NOVARTIS AG (CH) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274465-A1 | ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS | CD69, CD209, CD4 | TLR7 776/4885TLR8 1195/4885NUDT1 749/4885 |
| US-20120177681-A1 | Formulation of immunopotentiators | CD69, CD4, ICOS | TLR7 324/4885TLR8 516/4885NUDT1 656/4885 |
| US-20160213776-A1 | ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS | CD69, CD209, CD4 | TLR7 776/4885TLR8 1195/4885NUDT1 749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.